5 August, 2023
The World Economic Forum has highlighted phage technology as one of the Top 10 Emerging Technologies in 2023!
“At BioChimPharm, we are very proud of to be the significant contributor in the fight against AMR and a part of the Phage technology renaissance taking place across the globe” Rati Golijashvili, Managing Director.
World Economic Forum reveals the Top 10 Emerging Technologies of 2023 report:
1.Designer phages.
2.Flexible batteries.
3.Generative artificial intelligence.
4.Sustainable aviation fuel.
5.Metaverse for mental health.
6.Wearable plant sensors.
7.Spatial omics.
8.Flexible neural electronics.
9.Sustainable computing.
10.AI-facilitated healthcare.
“For more than a decade, the Forum has been surveying academics, industry leaders and futurists on the emerging technologies set to transform economies and societies. In doing so, the Top 10 Emerging Technologies of 2023 report seeks to help professionals across sectors and industries anticipate exponential technologies, interpret their implications and champion industry-shaping and society-serving applications” — Jeremy Jurgens, the Managing Director of World Economic Forum.
With antibiotic resistance becoming a critical global concern, this recognition highlights the importance of incorporating phage therapy into our arsenal of medical advancements.
This recognition by the World Economic Forum is a testament to the immense potential of phages in transforming healthcare and addressing the challenges posed by antibiotic resistance. The implications for patient care, public health, and the pharmaceutical industry are tremendous.
Phages are showing potential for treating microbiome associated diseases and revolutionizing the engineering of microbiomes for human, animal and plant health.
Phages are also being designed as feed supplements to enhance the growth of livestock, treat certain plant diseases and eliminate dangerous bacteria in food supply chains, in alignment with the World Health Organization’s “One Health” approach.
More about this groundbreaking technology and its role in shaping the future of medicine, read the World Economic Forum’s report here: https://ow.ly/SK2v50PsAh8
BioChimPharm (BCP) is a Georgian-based, multi-award-winning biopharmaceutical Company engaged in R&D, production and marketing of novel antibiotics against antimicrobial resistance (AMR) based on bacteriophages or simply phages. BCP’s mission is to eradicate the irrational use of antibiotics and to overcome antibiotic resistance challenge globally. Based on the World’s Oldest Phage Factory (1934), The Company possesses unique technological know-how and nearly 100 years of accumulated experience in R&D and the production of Phage based medications, used for treatment and prevention of infectious diseases including antibiotic resistant infections.
The Company utilizes paradigm shifting, phage technology platform that effectively and sustainably replaces antibiotics in both the human and animal health industries. The Phage based novel antibiotics provided by the Company, have helped millions of patients suffering from antibiotic-resistant infections globally. BCP is an ISO 9001-2015 and EU GMP (Good Manufacturing Practice) certified company.
